NISCI

is a multicenter, multinational, placebo controlled phase-II study for the safety and preliminary efficacy of intrathecal anti-Nogo-A [NG101] in patients with acute cervical spinal cord injury.

Registration numbers: HRB 156791 B (W)

VAT numbers: DE 229 548 135

Primary location: Berlin